RxDoctor Payments Data

Sudhir Athni, MD

Neurology · Macon, GANPI 1730294125

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $292,213 of the $431,631 with a category attached, or 67.7%. 21 manufacturers reported payments, led by Biogen at 42.0% of the total. Among neurology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$431,631in general payments, 2019–2025

Across 519 payments — averaging $831.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$181K
  • Argenx US, Inc.$88K
  • Johnson & Johnson$59K
  • Sanofi$36K
  • AstraZeneca$16K
  • ANI Pharmaceuticals, Inc.$15K
  • plus $35K from 15 others

What the payments were for

  • Consulting fees$65,24515%
  • Speaking & faculty fees$292,21368%
  • Travel & lodging$63,99715%
  • Food & beverage$10,1282%
  • Education$480%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$431,631 in reported general payments places this provider in the 95th percentile of 506 neurology providers in Georgia.

See all neurology providers in Georgia

Medicare billing

Part B allowed, 2024
$3,145,586
Medicare patients
93
Services billed
61,187

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BrilintaTicagrelor18$8,590
Memantine Hcl ErMemantine Hcl33$3,140
Gabapentin58$1,508
Primidone11$1,360
Leflunomide25$1,114
Modafinil17$970
Donepezil Hcl44$307
Lacosamide12$268
Zonisamide23$260
Topiramate16$190
Pramipexole DihydrochloridePramipexole Di-Hcl26$149
Quetiapine Fumarate20$138
Memantine Hcl12$131
Venlafaxine Hcl ErVenlafaxine Hcl13$101
Methylprednisolone13$86

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta$16,456$8,59018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 506 neurology providers in Georgia.

Other neurology in Macon

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →